**SUGGESTIONS FOR THE EMAILING AND SOCIAL MEDIA CAMPAIGN "ADOPT PARLIAMENTARIANS / MEPs**

**1. EMAIL TO BE SENT:**

Dear Ms/Mr,

We are a network of scientists, lawyers, doctors and citizens from different professions writing to you regarding the provision in ………….., now before Parliament, regarding the introduction of the COVID-19 Green Certificate. United by deep concern about the medium to long term implications of this instrument on our country's values and fundamental constitutional rights, we firmly believe that the proposed instrument represents an undue and serious limitation of the fundamental freedoms of citizens and lays the foundation for a profound discrimination and separation of Class A and Z citizens.

We therefore call on you to remove the aforementioned law.

The Privacy Guarantee has sent a formal warning to the Government (please check the one for your own country!) (<https://www.garanteprivacy.it/web/guest/home/docweb/-/docweb-display/docweb/9578184>) pointing out that "the rule just approved for the creation and management of "green certifications", the so-called vaccination passes, presents critical issues such as to invalidate, if not properly amended, the validity and operation of the system provided for the reopening of travel during the pandemic. Urgent action is therefore needed to protect people's rights and freedoms. First of all, the Garante notes that the so-called 're-opening decree' does not ensure an appropriate regulatory basis for the introduction and use of green certificates on a national scale, and is seriously incomplete in terms of data protection, lacking an assessment of possible large-scale risks to personal rights and freedoms. In contrast to the provisions of the European Data Protection Regulation, the decree does not precisely define the purposes for processing data on the health of Italians, leaving room for multiple and unpredictable future uses, potentially misaligned also with similar European initiatives. It does not specify who is the data controller, in violation of the principle of transparency, thus making it difficult if not impossible for data subjects to exercise their rights: for example, in the case of incorrect information contained in green certifications."

We are concerned not only by the aspects set out by the Privacy Guarantee but also by the lack of scientific basis to justify the introduction of such a tool. The scientific references at the bottom of the email.

The efficacy of vaccines, which are one of the three elements on which this certificate is based, is not at all proven and is still being tested. Covid-19 vaccines lack a viable mechanism of action against SARS-CoV-2 infection of the airways. Induction of antibodies cannot prevent infection by an agent such as SARS-CoV-2 that invades through the respiratory tract. Moreover, none of the vaccine trials have provided any evidence that vaccination prevents transmission of the infection by vaccinated individuals; urging vaccination to “protect others” therefore has no basis in fact.

This means that being vaccinated is not only no guarantee for public health but also presents an uncontrolled additional source of infection for others. The vaccines are dangerous to both healthy individuals and those with pre-existing chronic disease, for reasons such as the following: risk of lethal and non-lethal disruptions of blood clotting including bleeding disorders, thrombosis in the brain, stroke and heart attack; autoimmune and allergic reactions; antibody-dependent enhancement of disease; and vaccine impurities due to rushed manufacturing and unregulated production standards.

The risk-benefit calculus is therefore clear: the experimental vaccines are needless, ineffective and dangerous. Actors authorising, coercing or administering experimental COVID-19 vaccination are exposing populations and patients to serious, unnecessary, and unjustified medical risks.

In the coming days we will share more scientific information with you to support you in making an informed and responsible decision at the ballot box. We are keen to establish an open and transparent line of communication with you to ensure a meaningful and constructive dialogue.

Kind regards,

Scientific references:

[1] Le Bert, N.; Tan, A.T.; Kunasegaran, K.; Tham, C.Y.L.; Hafezi, M.; Chia, A.; Chng, M.H.Y.; Lin, M.; Tan, N.; Linster, M.; Chia, W.N.; Chen, M.I.; Wang, L.; Ooi, E.E.; Kalimuddin, S.; Tambyah, P.A.; Low, J.G.; Tan, Y. and Bertoletti, A. (2020) SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.[**Nature 584:457–462**](https://www.ncbi.nlm.nih.gov/pubmed/?term=32668444).

[2] Tarke, A.; Sidney, J.; Methot, N.; Zhang, Y.; Dan, J.M.; Goodwin, B.; Rubiro, P.; Sutherland, A.; da Silva Antunes, R.; Frazier, A. and al., e. (2021) Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees. [**bioRxiv -:x-x**](https://dx.doi.org/10.1101/2021.02.27.433180).

[3] Anonymous, (2020) [**Scientists uncover SARS-CoV-2-specific T cell immunity in recovered COVID-19 and SARS patients**](https://dx.doi.org/10.1101/2021.02.27.433180).

[4] Beasley, D. (2020) Scientists focus on how immune system T cells fight coronavirus in absence of antibodies. [**Reuters, 10/07/2020**](https://www.reuters.com/article/us-health-coronavirus-immunesystem-idUSKBN24B1D8).

[5] Bozkus, C.C. (2020) SARS-CoV-2-specific T cells without antibodies. [**Nat. Rev. Immunol. 20:463**](https://www.ncbi.nlm.nih.gov/pubmed/?term=32636475).

[6] Grifoni, A.; Weiskopf, D.; Ramirez, S.I.; Mateus, J.; Dan, J.M.; Moderbacher, C.R.; Rawlings, S.A.; Sutherland, A.; Premkumar, L.; Jadi, R.S. and al., e. (2020) Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. [**Cell 181:1489–1501.e15**](https://dx.doi.org/10.1016%2Fj.cell.2020.05.015).

[7] Mateus, J.; Grifoni, A.; Tarke, A.; Sidney, J.; Ramirez, S.I.; Dan, J.M.; Burger, Z.C.; Rawlings, S.A.; Smith, D.M.; Phillips, E. and al., e. (2020) Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. [[**back**](https://off-guardian.org/2021/05/05/covid-vaccines-necessity-efficacy-and-safety/)][**Science 370:89–94**](https://dx.doi.org/10.1126/science.abd3871).

[8] McCurry-Schmidt, M. (2020) Exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2. [**La Jolla Institute for Immunology**](https://tinyurl.com/corona-cross-immunity).

[9] Palmer, S.; Cunniffe, N. and Donnelly, R. (2021) COVID-19 hospitalization rates rise exponentially with age, inversely proportional to thymic T-cell production. [**J. R. Soc. Interface 18:20200982**](https://www.ncbi.nlm.nih.gov/pubmed/?term=33726544).

[10] Sekine, T.; Perez-Potti, A.; Rivera-Ballesteros, O.; Strålin, K.; Gorin, J.; Olsson, A.; Llewellyn-Lacey, S.; Kamal, H.; Bogdanovic, G.; Muschiol, S. and al., e. (2020) Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.[**Cell 183:158–168.e14**](https://dx.doi.org/10.1016/j.cell.2020.08.017).

[11] Drake, J. (2021) [**Now We Know: Covid-19 Vaccines Prevent Asymptomatic Infection, Too**](https://tinyurl.com/forbes-asymptomatic-infection).

[12] Bossuyt, P.M. (2020) Testing COVID-19 tests faces methodological challenges. [**Journal of clinical epidemiology 126:172–176**](https://dx.doi.org/10.1016/j.jclinepi.2020.06.037).

[13] Jefferson, T.; Spencer, E.; Brassey, J. and Heneghan, C. (2020) Viral cultures for COVID-19 infectivity assessment. Systematic review. [**Clin. Infect. Dis. ciaa1764:x-x**](https://doi.org/https:/doi.org/10.1093/cid/ciaa1764).

[14] Borger, P.; Malhotra, R.K.; Yeadon, M.; Craig, C.; McKernan, K.; Steger, K.; McSheehy, P.; Angelova, L.; Franchi, F.; Binder, T.; Ullrich, H.; Ohashi, M.; Scoglio, S.; Doesburg-van Kleffens, M.; Gilbert, D.; Klement, R.J.; Schrüfer, R.; Pieksma, B.W.; Bonte, J.; Dalle Carbonare, B.H.; Corbett, K.P. and Kämmer, U. (2020) [**External peer review of the RTPCR test to detect SARS-CoV-2 reveals 10 major scientific flaws at the molecular and methodological level: consequences for false-positive results**](https://doi.org/10.5281/zenodo.4298004).

[15] Mandavilli, A. (2020) [**Your Coronavirus Test Is Positive. Maybe It Shouldn’t Be**](https://www.nytimes.com/2020/08/29/health/coronavirus-testing.html).

[16] Cao, S.; Gan, Y.; Wang, C.; Bachmann, M.; Wei, S.; Gong, J.; Huang, Y.; Wang, T.; Li, L.; Lu, K.; Jiang, H.; Gong, Y.; Xu, H.; Shen, X.; Tian, Q.; Lv, C.; Song, F.; Yin, X. and Lu, Z. (2020) Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. [**Nat. Commun. 11:5917**](https://www.ncbi.nlm.nih.gov/pubmed/?term=33219229).

[17] Moghadas, S.M.; Fitzpatrick, M.C.; Sah, P.; Pandey, A.; Shoukat, A.; Singer, B.H. and Galvani, A.P. (2020) The implications of silent transmission for the control of COVID-19 outbreaks.[**Proc. Natl. Acad. Sci. U. S. A. 117:17513–17515**](https://www.ncbi.nlm.nih.gov/pubmed/?term=32632012).

[18] Johansson, M.A.; Quandelacy, T.M.; Kada, S.; Prasad, P.V.; Steele, M.; Brooks, J.T.; Slayton, R.B.; Biggerstaff, M. and Butler, J.C. (2021) SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. [**JAMA network open 4:e2035057**](https://dx.doi.org/10.1001/jamanetworkopen.2020.35057).

[19] Yeadon, M. (2020). What SAGE got wrong. [**Lockdown Skeptics**](https://lockdownsceptics.org/what-sage-got-wrong/).

[20] Ioannidis, J.P.A. (2020) Global perspective of COVID‐19 epidemiology for a full‐cycle pandemic. [**Eur. J. Clin. Invest. 50:x-x**](https://dx.doi.org/10.1111/eci.13423).

[21] Ioannidis, J.P.A. (2021) Reconciling estimates of global spread and infection fatality rates of COVID‐19: An overview of systematic evaluations. [**Eur. J. Clin. Invest. -:x-x**](https://dx.doi.org/10.1111/eci.13554).

[22] CDC, (2020) [**Science Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2**](https://tinyurl.com/cloth-masks-cdc).

[23] Orient, J.; McCullough, P. and Vliet, E. (2020)[**A Guide to Home-Based COVID Treatment**](https://aapsonline.org/covidpatientguide/).

[24] McCullough, P.A.; Alexander, P.E.; Armstrong, R.; Arvinte, C.; Bain, A.F.; Bartlett, R.P.; Berkowitz, R.L.; Berry, A.C.; Borody, T.J.; Brewer, J.H.; Brufsky, A.M.; Clarke, T.; Derwand, R.; Eck, A.; Eck, J.; Eisner, R.A.; Fareed, G.C.; Farella, A.; Fonseca, S.N.S.; Geyer, C.E.; Gonnering, R.S.; Graves, K.E.; Gross, K.B.V.; Hazan, S.; Held, K.S.; Hight, H.T.; Immanuel, S.; Jacobs, M.M.; Ladapo, J.A.; Lee, L.H.; Littell, J.; Lozano, I.; Mangat, H.S.; Marble, B.; McKinnon, J.E.; Merritt, L.D.; Orient, J.M.; Oskoui, R.; Pompan, D.C.; Procter, B.C.; Prodromos, C.; Rajter, J.C.; Rajter, J.; Ram, C.V.S.; Rios, S.S.; Risch, H.A.; Robb, M.J.A.; Rutherford, M.; Scholz, M.; Singleton, M.M.; Tumlin, J.A.; Tyson, B.M.; Urso, R.G.; Victory, K.; Vliet, E.L.; Wax, C.M.; Wolkoff, A.G.; Wooll, V. and Zelenko, V. (2020) Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). [**Reviews in cardiovascular medicine 21:517–530**](https://www.ncbi.nlm.nih.gov/pubmed/?term=33387997).

[25] Procter, {.B.C.; {APRN}, {.C.R.{.; {PA}-C, {.V.P.; {PA}-C, {.E.S.; {PA}-C, {.C.H. and McCullough, {.{.P.A. (2021) Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID-19). [**International journal of innovative research in medical science 6:219–221**](https://dx.doi.org/10.23958/ijirms/vol06-i03/1100).

[26] McCullough, P.A.; Kelly, R.J.; Ruocco, G.; Lerma, E.; Tumlin, J.; Wheelan, K.R.; Katz, N.; Lepor, N.E.; Vijay, K.; Carter, H.; Singh, B.; McCullough, S.P.; Bhambi, B.K.; Palazzuoli, A.; De Ferrari, G.M.; Milligan, G.P.; Safder, T.; Tecson, K.M.; Wang, D.D.; McKinnon, J.E.; O’Neill, W.W.; Zervos, M. and Risch, H.A. (2021) Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. [**Am. J. Med. 134:16–22**](https://www.ncbi.nlm.nih.gov/pubmed/?term=32771461).

[27] Anonymous, (2020) [**Real-time database and meta analysis of 588 COVID-19 studies**](https://c19early.com/).

[28] Hirschhorn, J.S. (2021) [**COVID scandal: Feds ignored 2016 law requiring use of real world evidence**](https://www.wnd.com/2021/04/covid-scandal-feds-ignored-2016-law-requiring-use-of-real-world-evidence/).

[29] Anonymous, (1998) [**Emergency Use of an Investigational Drug or Biologic: Guidance for Institutional Review Boards and Clinical Investigators**](https://tinyurl.com/fda-emergency-use).

[30] Anonymous, (2021) [**EMA assessment report: Comirnaty**](https://tinyurl.com/ema-comirnaty).

[31] Anonymous, (2020) [**FDA briefing document: Pfizer-BioNTech COVID-19 Vaccine**](https://www.fda.gov/media/144245/download).

[32] Giurgea, L.T. and Memoli, M.J. (2020) Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials. [**Vaccines 8:746**](https://dx.doi.org/10.3390/vaccines8040746).

[33] Bhakdi, S.; Chiesa, M.; Frost, S.; Griesz-Brisson, M.; Haditsch, M.; Hockertz, S.; Johnson, L.; Kämmerer, U.; Palmer, M.; Reiss, K.; Sönnichsen, A.; Wodarg, W. and Yeadon, M. (2021) [**Urgent Open Letter from Doctors and Scientists to the European Medicines Agency regarding COVID-19 Vaccine Safety Concerns**](https://tinyurl.com/d4ce-letter).

[34] Bhakdi, S. (2021) [**Rebuttal letter to European Medicines Agency from Doctors for Covid Ethics**](https://tinyurl.com/d4ce-rebuttal), April 1, 2021.

[35] Ulm, J.W. (2020) [**Rapid response to: Will covid-19 vaccines save lives? Current trials aren’t designed to tell us**](https://www.bmj.com/content/371/bmj.m4037/rr-19).

[36] Reimann, N. (2021) [**Covid Spiking In Over A Dozen States — Most With High Vaccination Rates**](https://tinyurl.com/forbes-reimann).

[37] Meredith, S. (2021)[**Chile has one of the world’s best vaccination rates. Covid is surging there anyway**](https://www.cnbc.com/2021/04/19/covid-chiles-coronavirus-cases-hit-record-levels-despite-vaccine-rollout.html).

[38] Bhuyan, A. (2021) Covid-19: India sees new spike in cases despite vaccine rollout. [**BMJ 372:n854**](https://www.ncbi.nlm.nih.gov/pubmed/?term=33785519).

[39] Morrissey, K. (2021) [**Open letter to Dr. Karina Butler**](https://archive.org/details/irish-covid-vaccination-deaths).

[40] Anonymous, (2021) [**Open Letter from the UK Medical Freedom Alliance: Urgent warning re Covid-19 vaccine-related deaths in the elderly and Care Homes**](https://tinyurl.com/tly3i6eb).

[41] Furer, V.; Zisman, D.; Kibari, A.; Rimar, D.; Paran, Y. and Elkayam, O. (2021) Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. [**Rheumatology -:x-x**](https://web.archive.org/web/20210501011529/https:/www.ncbi.nlm.nih.gov/pubmed/?term=33848321).

[42] Anonymous, (2021) [**Covid-19 vaccines: ethical, legal and practical considerations**](https://pace.coe.int/en/files/29004/html).

[43] Tseng, C.; Sbrana, E.; Iwata-Yoshikawa, N.; Newman, P.C.; Garron, T.; Atmar, R.L.; Peters, C.J. and Couch, R.B. (2012) Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. [**PLoS One 7:e35421**](https://www.ncbi.nlm.nih.gov/pubmed/?term=22536382).

[44] Bolles, M.; Deming, D.; Long, K.; Agnihothram, S.; Whitmore, A.; Ferris, M.; Funkhouser, W.; Gralinski, L.; Totura, A.; Heise, M. and Baric, R.S. (2011) A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. [**J. Virol. 85:12201–15**](https://www.ncbi.nlm.nih.gov/pubmed/?term=21937658).

[45] Weingartl, H.; Czub, M.; Czub, S.; Neufeld, J.; Marszal, P.; Gren, J.; Smith, G.; Jones, S.; Proulx, R.; Deschambault, Y.; Grudeski, E.; Andonov, A.; He, R.; Li, Y.; Copps, J.; Grolla, A.; Dick, D.; Berry, J.; Ganske, S.; Manning, L. and Cao, J. (2004) Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. [**J. Virol. 78:12672–6**](https://www.ncbi.nlm.nih.gov/pubmed/?term=15507655).

[46]Czub, M.; Weingartl, H.; Czub, S.; He, R. and Cao, J. (2005) Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. [**Vaccine 23:2273–9**](https://www.ncbi.nlm.nih.gov/pubmed/?term=15755610) [[**back**](https://off-guardian.org/2021/05/05/covid-vaccines-necessity-efficacy-and-safety/)]

[47]Tinari, S. (2021) The EMA covid-19 data leak, and what it tells us about mRNA instability. [**BMJ 372:n627**](https://pubmed.ncbi.nlm.nih.gov/33692030/)

[48] Anonymous, (2021) [**Interview with Dr. Vanessa Schmidt-Krüger**](http://enformtk.u-aizu.ac.jp/howard/gcep_dr_vanessa_schmidt_krueger/), Hearing #37 of German Corona Extra-Parliamentary Inquiry Committee 30 January, 2021.

**2. TWITTER AND FB MESSAGES TO POST** (ALWAYS USE THE #NOcovidpass HASTAG) SATURDAY AND SUNDAY (8 AND 9 MAY)

Tweet #1 (copy/paste the text below into a Tweet)

The COVID-19 Green Certificate is a disproportionate, inefficient and unfair obstacle to the free movement of Italian citizens. The proposed Article 9 is neither scientifically nor legally acceptable. #NOcovidpass

Tweet #2 (copy/paste the text below into a Tweet)

#NOcovidpass:

🛑 Violates freedom of movement and movement guaranteed by the Constitution

✋ Discriminates against those who cannot or do not want to be tested or vaccinated

👎 Does not guarantee the protection of privacy

**Always remember to tweet MEPs (@matteosalvinimi etc.)**